Intellia Therapeutics, Inc. - FORM S-1 - EX-23.1 - April 11, 2016

Attached files

file filename
S-1 - FORM S-1 - Intellia Therapeutics, Inc.d67753ds1.htm
EX-3.4 - EX-3.4 - Intellia Therapeutics, Inc.d67753dex34.htm
EX-4.1 - EX-4.1 - Intellia Therapeutics, Inc.d67753dex41.htm
EX-3.2 - EX-3.2 - Intellia Therapeutics, Inc.d67753dex32.htm
EX-3.3 - EX-3.3 - Intellia Therapeutics, Inc.d67753dex33.htm
EX-3.1 - EX-3.1 - Intellia Therapeutics, Inc.d67753dex31.htm
EX-16.1 - EX-16.1 - Intellia Therapeutics, Inc.d67753dex161.htm
EX-10.3 - EX-10.3 - Intellia Therapeutics, Inc.d67753dex103.htm
EX-21.1 - EX-21.1 - Intellia Therapeutics, Inc.d67753dex211.htm
EX-10.2 - EX-10.2 - Intellia Therapeutics, Inc.d67753dex102.htm
EX-10.7 - EX-10.7 - Intellia Therapeutics, Inc.d67753dex107.htm
EX-10.8 - EX-10.8 - Intellia Therapeutics, Inc.d67753dex108.htm
EX-10.5 - EX-10.5 - Intellia Therapeutics, Inc.d67753dex105.htm
EX-10.4 - EX-10.4 - Intellia Therapeutics, Inc.d67753dex104.htm
EX-10.10 - EX-10.10 - Intellia Therapeutics, Inc.d67753dex1010.htm
EX-10.11 - EX-10.11 - Intellia Therapeutics, Inc.d67753dex1011.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement on Form S-1 of our report dated March 16, 2016 relating to the financial statements of Intellia Therapeutics, Inc. (successor to Intellia Therapeutics, LLC) and subsidiaries appearing in the Prospectus, which is part of this Registration Statement.

We also consent to the reference to us under the heading “Experts” in such Prospectus.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

April 11, 2016

Intellia Therapeutics, Inc. Reports